The treatment of kidney diseases consumes a substantial amount of the health budget for a relatively small fraction of the overall population. If the nephrological community and society do not develop mechanisms to contain those costs, it will become impossible to continue assuring optimal outcomes and quality of life while treating all patients who need it. In this article, we describe several mechanisms to maintain sustainability of renal replacement therapy. These include (i) encouragement of transplantation after both living and deceased donation; (ii) stimulation of alternative dialysis strategies besides classical hospital haemodialysis, such as home haemodialysis, peritoneal dialysis or self-care and necessitating less reimbursement; (iii) promotion of educational activities guiding the patients towards therapies that are most suited for them; (iv) consideration of one or more of cost containment incentives such as bundling of reimbursement (if not affecting quality of the treatment), timely patient referral, green dialysis, start of dialysis based on clinical necessity rather than renal function parameters and/or prevention of CKD or its progression; (v) strategically planned adaptations to the expected growth of the ageing population in need of renal replacement; (vi) the necessity for support of research in the direction of helping as large as possible patient populations for acceptable costs; and (vii) the need for more patient-centred approaches. We also extend the discussion to the specific situation of kidney diseases in low-and middle-income countries. Finally, we point to the dramatic differences in accessibility and reimbursement of different modalities throughout Europe. We hope that this text will offer a framework for the nephrological community, including patients and nurses, and the concerned policy makers and caregivers on how to continue reaching all patients in need of renal replacement for affordable expenses.
I N T R O D U C T I O N
Even before end-stage renal disease (ESRD) develops, the number of hospitalizations and health costs increase, especially in the months preceding dialysis, due to the presence of complications and/or comorbidities [1, 2] . Dialysis and transplantation can prolong survival of ESRD, but generate substantial health expenditures [3, 4] , and increase the pressure on social security when it is available, such as in high-and some middle-income countries [3] . In low-income countries, it is impossible to reimburse treatment for every ESRD patient, and as a consequence, most families are unable to pay long-term dialysis out of pocket [5] .
In contrast with the stable or even decreasing incidence of renal replacement in most developed countries, their prevalence keeps rising. Projections for the coming decade, e.g. for USA, predict a further increase [6] . At the same time, the treated population becomes older and sicker, with more complications, hospitalizations and hidden costs [7] . In other parts of the world, incidence of ESRD steadily grows together with its causes [8] . The total societal cost of ESRD patients is severalfold that of non-ESRD patients, whereas the percentage of beneficiaries is proportionally smaller than the per cent of money spent [9] . Nevertheless, regulators worldwide hesitate to reorganize the financing of renal replacement therapy (RRT) [10] .
It should be noted that the options presented here are a selection of solutions as proposed in literature. They should not be perceived as the sole solutions, and there might be other valid alternatives. In addition, although ethical aspects are discussed sporadically throughout this text, each of the proposed subheadings may by themselves be the topic of heated ethical debate, where not every expert might agree with our suggestions. Nevertheless, we tried to offer an in-depth synopsis of the current potential options for reducing costs of RRT. These might prove necessary to sustain the treatment of as many affected patients as possible.
D I S C R E PA N C I E S I N R E I M B U R S E M E N T
Reimbursement markedly differs between strategies ( Figure 1 ) [11] and rarely reflects real costs. Transplantation is the least expensive option for society, especially in young patients with a long life expectancy [12] . Among dialysis strategies, those performed outside the hospital [home haemodialysis, peritoneal dialysis (PD), self-care] are most cost-effective ( Figure 1 ) [11] . Although they offer freedom and self-control [13] , and are favoured in patient [13] , and nephrologist surveys [14] , their application remains disproportionally low [15] . Unjustified fear for technical or medical complications often prevails [14, 16] , a balance which is further tipped by suboptimal reimbursement [11] , pushing providers towards the financially more rewarding strategies [15] . However, a fair compensation for home strategies is still no solution if no concomitant education and training are provided to patients, nurses and physicians [17] .
Discrepancies in reimbursement among countries are substantial [11] and parallel to overall national health expenditures [18] . The financial surplus of liberal reimbursement of some modalities is often used by care providers and hospital managements to cover inadequate reimbursement and income of other, nonnephrological departments. Financial restriction carries a risk of patient selection (cherry picking) [19] and of decreasing standards of care, but it may offer opportunities to improve the balance between expenses and income [20] if done properly and with the correct incentives. Financial compensations for invalidated patients (e.g. aged, diabetics) [11] may encourage dialysing patients who might be better off with conservative treatment (e.g. the debilitated old).
S P E C I F I C A S P E C T S R E L AT E D TO LOW -CO S T S T R AT E G I E S
Therapeutic approaches to CKD5 (ESRD) and their relative cost are summarized in Figure 2 .
Transplantation
Transplantation combines cost containment with optimal survival and quality of life [12] , but is restricted to the patient population with the most favourable condition and few or no comorbidities. Enhancing organ procurement is up till now the only option to prevent continuously growing waiting lists. Kidneys can be harvested from both deceased and living donors, but few countries are strong in the two options, and many fail for both.
Living donation can be stimulated by preemptive donation, donor exchange programmes or a more fair reimbursement of donors to cover losses of income or extra costs in relation to the intervention (Table 1) [21] [22] [23] .
For deceased donation, presumed consent (opting-out, considering everyone not officially declaring his/her disagreement as a potential donor) is applied by many European countries (Table 1) [24] . A recent study attributed a high transplant rate to countries applying presumed consent [25] , although there are exceptions [24, 25] . Transplantation rate in Croatia grew exponentially during the past decade, because of the introduction of opting-out policy, but also better organization, F I G U R E 1 : Relative reimbursement rates per week in $ in vigour at the end of 2011. Values obtained were normalized versus the approach in vigour in the USA, where at that moment, all strategies were reimbursed at $689 per week. (A) Comparison for hospital haemodialysis and CAPD for seven different countries. (B) Comparison for the Netherlands and Germany for five different dialysis modalities. Substantial differences exist among different countries and strategies. Apart from Germany, reimbursement for CAPD is lower than for hospital haemodialysis. These data should be considered as a momentary snapshot, essentially aiming at displaying discrepancies rather than the actual status. US: United States; C: Canada (Province of Ontario); B: Belgium; F: France; G: Germany; N: the Netherlands; UK: United Kingdom. Hosp HD: hospital haemodialysis; home HD: home haemodialysis; CAPD: continuous ambulatory PD; APD: automated PD. Modified from Vanholder et al. [11] . reimbursement, educational initiatives and enrolment into the large Eurotransplant network were key contributing factors [26] . Whereas presumed consent can be seen as lack of free choice [24] , individuals with true objections can still opt out, since in most countries the permission of the family is asked [25] . Nevertheless, politicians in several countries are hesitant to adopt such a system, as was the case less than 2 years ago in Switzerland (http://www.swissinfo.ch/eng/government-rejectspresumed-consent/35180768).
Further options with the potential to enhance deceased transplantation are extending donor selection to hepatitis C-and HIV-positive donors for acceptors with the same disease, accepting non-heart-beating donors and, especially for older recipients, donors older than 60 or older than 50 with comorbidities ('old for old') ( Table 1) . In a retrospective analysis by Heilman et al., transplant recipients from donors with severe acute kidney injury (AKI) had similar kidney functions, rejection rates and morphologic appearances of their grafts as patients receiving kidneys from standard donors [27] . The study, however, contained a limited number of cases, and follow-up extended over only 1 year [27] . It has been noted that grafts from expanded donation may be suboptimal, generating more costs than regular donor kidneys [28] .
Organ trade is the subject of fierce ethical debate. Although potentially decreasing societal cost, it is impossible to exclude exploitation or even coercion, while also the health of the recipient can be jeopardized if medical management and follow-up are insufficient [29] . Even the example of Iran, where organ trade is centrally regulated without following free market principles, should be considered with reserve [30, 31] . In contrast, ethically justified financial compensation of voluntary living donors, e.g. for loss of income because of the unavoidable work interruption, might be considered, if positively impacting medical expenditures. In a large international survey in high-income countries, correction of disincentives for living donors, such as unjust reimbursement, was deemed the only acceptable compensation system in this context [32] .
Not only donation but also waitlisting is often suboptimal. Valid older candidates, women and racial minorities tend to be ignored [33] [34] [35] . Lack of information especially hampers transplantation of women, non-Caucasians, obese, mentally debilitated persons and patients with diabetes [36] . Time and effort spent on informing patients may differ markedly among different centres, so that also the basic philosophy and the background of a unit seem to play a role [36] .
Structured research could be of help to identify the factors affecting donation per country, in an attempt to improve it. F I G U R E 2 : Therapeutic approaches to CKD5 (ESRD), and their relative costs, graded from the lowest to the highest by green→ yellow→ orange→red. Cost estimates are only approximate and take into account a general, global picture. Deviations from this standard picture may apply for specific individuals, regions or countries. Peritoneal dialysis Several outcomes of PD are at least similar to those of haemodialysis [16, 37] . Preservation of residual renal function [38] , results of transplantation [39] and quality of life are in most series superior to PD [40, 41] .
In most developed countries, PD offers the most optimal cost-effectiveness ratio among dialysis strategies [3, 42] as it necessitates minimal labour force and less hardware [42] , and lowers indirect costs [43] . The gap between the costs of PD and haemodialysis is smaller in emerging countries, mainly due to the need to import PD fluids [40] .
Despite equal outcomes and the lowest reimbursement cost among dialysis strategies [11, 44] , and although freedom, convenience, self-care and simplicity of treatment are viewed as positive by most patients [45] , worldwide prevalence of PD is steadily decreasing [46] , very likely because choice among strategies is more influenced by hospital economics, availability of labour force, need to occupy open hospital haemodialysis positions and reluctance to invest in PD, rather than by societal or clinical arguments [44] . Renal replacement strategies spontaneously seek the most profitable ratio [11, 15] , with PD being more frequent in public health care, compared with private or mixed systems [47] . However, also nonfinancial factors play a role: elderly and handicapped patients are often excluded, ignoring the option of assisted help [48] .
Increasing reimbursement is not an absolute guarantee for increased use [17] . Enrolment into PD may remain low when the start of dialysis is not well planned and not accompanied by education and troubleshooting advice [49] . In addition, any well-working PD programme needs to be backed by robust haemodialysis infrastructure, to offer adequate backup if PD treatment becomes inadequate or for another reason is to be discontinued.
Alternative haemodialysis strategies
Reimbursement and cost of home haemodialysis occupy an intermediate position between PD and hospital haemodialysis ( Figure 1 ) [4, 11, 41, 42] . Irrespective of their current therapy, patients prefer treatment at home [13] , which also has been linked to an outcome advantage to hospital haemodialysis [50] .
By facilitating alternative time frames to the classical thrice weekly 3-5 h regime, home dialysis improves removal of solutes with potential impact on outcome [51] . Better outcomes have been demonstrated in mostly observational studies [51] . A comparison of two extended nocturnal haemodialysis programmes with United States Renal Data System data showed similar survival as with deceased donor transplantation [52] . In contrast to a positive impact on surrogate end points such as predialysis phosphorus or systolic blood pressure [53] , controlled trials, however, failed to show superiority for frequent home haemodialysis on hard outcomes [53] while they were suggestive of increased risk for vascular access problems [53] and a more rapid decline in renal function [54] .
Although low cost, better quality of life and patient preference make it the preferred haemodialysis option in any valid candidate, home haemodialysis remains underutilized, in part related to unjustified fear for technical adverse events [55, 56] .
From the positive side, home haemodialysis is also perceived as improving freedom, flexibility and well-being [56] . More compact and/or simpler systems may be helpful to make home dialysis easier to perform. The Dutch Kidney Foundation currently has commissioned a programme encouraging the development of such compact dialysis machines (Neokidney project-http:// www.neokidney.nl/index.php/nl/).
Self-care haemodialysis, a hybrid between home and hospital haemodialysis, is aiming at dialysing in centre with minimal support [50] as a novel option for cost containment [11] .
E D U CAT I O N
A large number of more or less justified factors are perceived as barriers, either for PD or home haemodialysis, but many of these may be surmountable with the appropriate measures or education (Table 2 ) [57] . Predialysis education even seems to decrease costs once dialysis is started, especially by preventing complications such as access problems [58] . Although in a large survey, patients generally perceived their education as satisfactory, many respondents could not remember having received education on other modalities than their current one, or on home dialysis strategies, or on predialysis kidney care [59] . As patients also perceived dietary and fluid restrictions as being disorienting and cumbersome, specific educative strategies to enhance motivation in this regard should be considered as well, which would be of help avoiding progression of renal failure [60] .
Involvement in therapy selection enhanced satisfaction with treatment [59] . However, initial choice for home strategies is often abandoned afterwards before there is a need to start renal replacement, due to external influences, e.g. by family or medical professionals not directly involved in renal care [61] . Hence, reevaluation of patient choices and reinforcement of their motivation should be sustained once the initial choice has been made [61] .
Even in countries where efforts have been made to increase PD and home haemodialysis treatment, application of these strategies often remains low. One of the reasons may be that the technical possibilities for the application of these procedures, as they are available today, have been reached. Taking this into account, simpler and more compact systems, as discussed above (Neokidney project), making home strategies easier to perform, may help favouring transition to those systems.
F I N A N C I A L I N C E N T I V E S
A reduction in renal replacement costs is compulsory as financial deficits of social security grow and economic crises reduce the financial reserves of governments [3] .
Bundling
Bundling of dialysis reimbursement can be defined as funding dialysis itself but also several other dialysis-related expenses within one package. Although what is contained in the basket may differ from country to country, it may, next to dialysis itself and all supplies, equipment and services needed to perform this dialysis, consist as well of erythropoiesis-stimulating agents (ESAs), injectable or oral drugs linked to dialysis, diagnostic laboratory tests and/or training (in the case of home dialysis). Bundling dialysis expenses into one basket may have positive (rationalized balance between expenses and income, consultation among stakeholders, patient-centred decision-making, less costs for patients, improved quality assessment, increased measuring of performance) [19, 20] but also negative effects (cherry picking, e.g. by firing noncompliant patients, shifting to cheaper but less adequate therapies) [19] . An effort should be made to better map the pros and cons of bundling.
The negative aspects of bundling can be compensated by pay for quality initiatives, whereby better processes and/or outcomes are rewarded via extra bonuses. Such extras for supposed good practice, e.g. for reaching a target Kt/V or haemoglobin levels [11] , are, however, based on current opinion that may appear incorrect at a later stage; e.g. for haemoglobin, the international community was forced several times to adapt thresholds in the past few years, due to shifts in evidence [62] . Extra bonus can also be given per number of patients treated by transplantation or nonhospital dialysis [11] . Currently, no studies have assessed the real impact of such measures. In addition, one aspect that at this moment is almost entirely left out of consideration is what patients and their families perceive as good quality therapy [63] . This should be incorporated in future therapeutic quality assessments.
Timely referral
In patients only seen by the nephrologist for the first time shortly before dialysis is to be started, extra expenses are substantial, because of complications due to more severe comorbidities [64] and longer hospitalization [65] , and a lack of appropriate dialysis access system creating additional complications. Late-referred patients tend to die early during their follow-up [64] . Inadequate insurance increases the risk of late referral and related mortality [64] . Enrolment into home or self-care strategies or transplantation often remains low if start of renal replacement is not well planned and not accompanied by education [36, 49, 66] .
Profit status of renal replacement units
Profit status of dialysis units may have socio-economic impact. For-profit centres prescribed more erythropoetin than nonprofit units when US reimbursement was proportional to the number of patients reaching at least a 33% haematocrit [67] . In Italy, PD is applied less in regions where more patients are treated in for-profit centres [68] , and patient education on transplantation may be less intensive, as again observed in the USA [36] . All these studies were confined, however, to restricted geographic areas and thus do not necessarily apply globally. Nevertheless, they suggest that decision-making about socioeconomically impacting factors is unequally distributed among centres, at least in part depending on financial driving forces.
Green dialysis
By an excessive use of water, electricity and plastics, and an ample production of waste and operation in nonecological buildings, dialysis is not environment friendly [69, 70] . Solar energy-based haemodialysis is an appealing option. Dialysate, substitution fluid for haemodiafiltration and rejection fluid of reverse osmosis [69] , contribute to water consumption, which may be rationed by extracorporeal adsorption, recycling rejected reverse osmosis water or spent dialysate [69] or passing spent dialysate several times through the filter combined to extended dialysis, which especially for difficult to remove molecules such as phosphorus or β 2 -microglobulin, rather increases than decreases removal [71] . Green dialysis increases costs in the short term as an investment in equipment has to be made, but can reduce expenditure in the longer term (Table 3) .
Part of the strategies for the prevention of the progression of kidney failure like exercising and reduction of meat protein consumption at the same time also improve the carbon footprint.
Reuse Even if dialyser reuse allows more patients to be reached for less expenses while discarding less solid materials [72] , its practice remains controversial [73, 74] , partly because the trials addressing its safety are qualitatively deceiving. Water permeability of dialysers, which is related to clearance capacity, is dramatically modified by reuse [75] . Some of the alleged advantages, such as an improvement of membrane biocompatibility, have in the meanwhile been offset by the introduction of newer polymer materials [72] . Although avoiding chemicals, heat sterilization may have other ecological disadvantages or cost effects, and can, like any reuse method, only be accepted if safety is completely ensured.
Postponed start of dialysis
Several observational trials show that start of dialysis at high glomerular filtration rate (GFR) results in higher mortality [76] , which in one study was confirmed even if bias by start of dialysis because of precarious condition was excluded [77] . In another study, however, correction by propensity scoring did not sustain the differences in outcomes [78] . The randomized IDEAL trial showed no advantage of early start in really asymptomatic patients [79] , shifting the current paradigm of starting dialysis towards considering the presence of symptoms rather than estimated glomerular filtration rate (eGFR) [80, 81] . The implementation of a later start is, together with prevention, a potential cause of the current decreasing incidence of dialysis patients [82] . Early start of dialysis also implies higher costs without a gain in quality of life [83] .
Prevention of progression
Adequate prevention not only reduces costs by postponing renal replacement [84] , but also by reducing the number of hospitalizations in the pre-ESRD stage ( Figure 3 ) [2] . If markers are reliable, and an effective treatment is available, screening is one of the cornerstones for timely prevention (Figure 4 ). An ethical drawback is that novel risks can be generated, especially if too many false positives are selected for treatment, while individual freedom is affected [85] . Nevertheless, screening has especially been suggested to be cost-effective in diabetics and hypertensive patients [86] , and studies of the urinary proteome may become helpful in future in detecting progressive cases early and • Reduce power consumption
• Use alternative power options (e.g. solar energy)
• Develop optimal waste management F I G U R E 3 : Different measures that could contribute to prevention of CKD or of progression of CKD. The relative cost is scaled in a similar way as in Figure 2 , with, however, only two levels, green-minimal cost and yellow-moderate. Cost estimates are only approximate and take into account a general, global picture. Deviations from this standard picture may apply for specific individuals, regions or countries.
predicting outcomes [87] . A community-wide follow-up programme of identified cases at risk managed to decrease incidence of CKD in a mainly socially deprived UK population [88] .
Patient capacity to implement the necessary lifestyle changes to slow progression may be limited by lack of knowledge and ability to interact with health-care providers [89] .
The currently used markers of progression, albuminuria and decreased eGFR, become apparent late during evolution [90] . Only a small fraction of positives will evolve towards the end stage [91] . Systematic treatment of all those with albuminuria may automatically cause the useless treatment of some individuals, especially those without other risk factors [92] . More specific biomarkers could narrow the number needed to treat [90] , but for each marker, a careful cost-effectiveness assessment would be useful, considering the number to screen and to treat, and length of follow-up and treatment of patients made aware of their 'disease' by the screening. The societal benefit of obviating RRT should exceed the cost of such a detection and prevention programme. The same probably applies to mostly expensive prevention of orphan diseases [93] . The earlier a preventive intervention is aimed to modify the evolution of kidney failure, the higher the number to treat, and the more specific or less expensive markers and treatment should be to compensate for the larger target population. Screening without education may be futile and may turn out especially cost-effective if targeting at avoiding lifestyle-dependent comorbidities causing CKD such as obesity, diabetes or hypertension (Figure 3 ) [94] , particularly in the high-risk group of subjects with lower level of education [95] .
Avoiding start on dialysis of those at high risk of early death would be acceptable if the predictors used are reliable and have a high positive predictive value with a socially accepted cut-off value. By lack of such a marker, it might be useful to start with a time-restricted therapeutic attempt, which is abandoned if prespecified targets are not reached.
It is clear that, at least for Europe, there is a lack of streamlined action throughout different countries, with huge differences in surveillance strategies, and guidance initiatives, and low and variable awareness about CKD among policy makers, providers and general public [96] .
A G E I N G
The fast increase of age in those treated by RRT is an emerging problem proportionate to the rising number of elderly in the general population, and the high prevalence of CKD among them [97] . Especially, disabled elderly generate substantial health costs [98] .
Need for renal replacement may be not as stringent in the elderly as in younger populations, as CKD in most elderly does not tend to progress rapidly [99] , while a moderately decreased GFR does not markedly change outcomes [100] . The surplus mortality of an older CKD versus non-CKD population is much smaller than in younger age groups [101] .
Yet, the number of elderly enrolled in dialysis increases progressively [102] , even if the apparent survival advantage over conservative treatment [48] is largely spent in-hospital, either on dialysis or as inpatient [49] , and medical costs are higher [7] . Mortality remains high, especially early after start [102] . Many elderly regret having started dialysis [103] , experiencing a loss of independency, quality of life and functional status [104, 105] . However, these drawbacks do not prevail if comorbidities are absent [49, 106, 107] . Thus, decision to start RRT in the elderly is not evident. Success strongly depends on the patient's condition and should preferably be based on shared decisionmaking [108] . The difficulty is to find an ethically justified balance between avoiding overtreatment of patients not profiting from dialysis while, at the other side of the coin, not withholding treatment from those with potential advantages.
In frail elderly, who often die early after start without real benefit, conservative palliative care should be considered [102] as a more humane solution than the start of dialysis, which indirectly also may impact societal burden. The choice for dialysis or not should be favoured only after shared decision-making with active patient participation [108, 109] , and in case the path of no dialysis is chosen, palliative support should assure as much as possible reasonable quality of life and symptom control [110, 111] .
Transplantation in the elderly is linked to lower mortality and cost than in older waitlisted patients remaining on dialysis [12, 34] . In spite of the current increase in transplant acceptors [112] , a predictive model discerning valid old transplant candidates showed that >70% of elderly who were fit enough were not transplanted [34] . The shortage of donor organs, combined with the fear to discriminate the fastest growing section of the population, led to specific programmes like old for old [113] with the risk, however, of channelling lower-quality organs to the most fragile population. However, excluding kidneys of younger donors for older recipients increased overall posttransplant survival by 3 years with a cost saving of 1.5 billion dollars over 12 years, just by taking into account the fact that survival of young donor kidneys exceeded the patient survival of older recipients, hence indirectly keeping younger patients longer on dialysis while reducing the time during which benefit is taken from the transplant kidney [114] . 
E M E R G I N G WO R L D
While the above problems necessitate a mental change in the 'developed' world, the situation is even more precarious in the emerging world where therapies are only partly reimbursed, transplantation is exceptional and importation of material including PD fluids increases cost. On the other hand, labour force is cheaper, which relatively favours labour-intensive therapies like hospital haemodialysis. Governments should find solutions specific to the local situation from which the 'developed' world may learn as well in these times of crisis.
As the aim is to help as many people with kidney disease as possible against acceptable costs, prevention, rather than renal replacement, is very likely the optimal backbone approach [115] ; this would avoid the large number of patients with high-risk conditions such as hypertension or diabetes now suffering a bleak outcome in those emerging countries because they evaded screening and at the end stage cannot get renal replacement [116] .
Hypertension is extremely common in sub-Saharan Africa [117] . Diabetes and obesity are frequently poorly controlled [116] . Due to ineffective detection programmes even among highrisk patients, the treatment is rarely appropriate [118] , increasing the prevalence of CKD because the majority of those affected are unaware of their condition [116] . A lack of specialists, mainly due to brain drain [115] , might force screening to be conveyed to other medical professionals such as general practitioners or nurses.
PD might be an effective option [119] , but difficult and lengthy transport of material increases costs dramatically [119] , especially in sub-Saharan Africa, even if the end product is generated locally [120] . Socio-economic factors, inadequate microbiological diagnosis of peritonitis and lack of infrastructure and qualified workers are some of the other factors with a negative impact on the implementation of PD [119] . Patient selection becomes almost unavoidable, at the detriment of older, sicker and socio-economically disadvantaged patients [121] . Some countries are rationing dialysis allowing them to take on more patients [122] . Transplantation is extremely exceptional: UK performs more transplantations than the whole of Africa [120] .
As patients have to carry the costs of their dialysis partially or entirely by themselves, perspectives are minimal if no transplantation is available, creating a social disequilibrium resulting in a survival advantage for wealthier patients. In Nigeria, the large majority of dialysis patients can no longer afford dialysis after maximum a few months of treatment [123] .
Perspectives for AKI are somewhat brighter, as in the emerging world, chances for recovery are considerable, but dialysis treatment remains exceptional [120] .
However, it is now well accepted that even silent episodes of AKI can contribute to the development or progression to chronic kidney disease [124] . This has striking socio-economic and public health effects, not least in low-income countries where individuals are already at risk for chronic disease because of low birth weight or poor nutrition. Furthermore, in view of the known association of end-stage and chronic kidney disease with cardiovascular comorbidity, survival from AKI leading to a need of chronic dialysis has the potential to increase the burden of cardiovascular disease.
R E S E A R C H
A shift of research focus from assessing expensive sophisticated strategies towards helping larger numbers of patients against acceptable costs, and from renal replacement to prevention and detection of progression, is a matter of ethical concern. Societal cost-benefit of the different available options should be calculated carefully. Establishing research priorities could benefit from a prespecified and transparent process engaging also patients so that their views and aspirations are covered by research targets [125] .
CO N C L U S I O N S
Harmonization among countries with reimbursement in function of real cost should be considered but not be limited to nephrology and not only restrict high reimbursement but also offer more support where reimbursement is insufficient. A transparent analysis of real costs of all available therapeutic options is necessary. Ethical considerations by political decision makers and medical professionals necessitate a change in philosophy from a market and hospital-oriented to societyand patient-oriented health economy. This is probably the only valid option to continue treating all patients in need for RRT. Patient views should be taken into consideration. In addition, efforts should be made to correctly inform policy makers in order to help them making the right decisions.
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R E F E R E N C E S A B S T R AC T
There is little data to guide clinicians on the optimal management of immunosuppression in patients whose kidney transplant has failed and who have returned to dialysis. Nor is there robust data on whether to perform a transplant nephrectomy. Finally, management of late stage chronic kidney disease, including deciding on dialysis initiation, modality and access planning, must occur simultaneously with efforts aimed at preserving the failing kidney and residual renal function for as long as possible. In this article, we will review the evidence on these topics and suggest areas for improvement.
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I N T R O D U C T I O N
The return to dialysis is among the difficult transitions that a patient whose transplanted kidney has failed must make. Sometimes it is permanent, and sometimes it is only temporary while waiting for another kidney. An important decision for the patient's nephrologist is whether and how much immunosuppression to continue, balancing the risk of rejection and the
